Managing Director Jason Wittes of Brean Capital says Globus Medical Inc (GMED) is in a strong position right now. He says the company is a $2 billion-plus market cap name that is well-capitalized and able to service markets as effectively as J&J or Medtronic.
“But they still have that focus and, most would argue, a significantly better product portfolio offering than those two largest players,” he says. “They’re unique in having the right scale and focus.”
That, Wittes says, is why Globus is consistently growing its top line in the low double digits. He anticipates that the company can continually drive strong topline growth, given its current position.
“Globus already has best-in-class operating margins, but I see opportunity for accelerated growth as it expands into trauma — an area where its aggressive product development and sales strategy could prove even more successful than it was in spine, given it’s a less competitive space,” Wittes says.
Endologix (ELGX) Expands Ventana and Nellix Medical Devices into Europe
August 08, 2013
Priceline.com Inc (PCLN) Expands Booking.com Into the U.S.; Near-Term Growth Prospects Remain High
October 18, 2013
Molson Coors Brewing Company (TAP) Expands Internationally and Into Craft Beer While Trading Inexpensively
March 05, 2013
Goldcorp (GG) Expands Gold Mining with Discipline; Gold Fields Ltd. (GFI) Sees Revalue Opportunity
December 19, 2012
Trauma Surgery Director Turned Equity Analyst Picks Medtech Stock Winners
June 09, 2023
